Emerging therapies for graft-versus-host disease

Area of Science:

• Hematopoietic Stem Cell Transplantation
• Immunology

Background:

• Graft-versus-host disease (GVHD) is a significant complication of hematopoietic cell transplantation (HCT).
• GVHD involves distinct phases: recipient conditioning, donor T cell activation, and effector cell-mediated damage.

Purpose of the Study:

• To review current and emerging pharmacological agents for GVHD prevention and treatment.
• To discuss the impact of various agents on different phases of the GVHD cascade.

Main Methods:

• Discussion of standard and investigational agents including sirolimus, mycophenolate mofetil (MMF), pentostatin, alemtuzumab, daclizumab, and infliximab.
• Analysis of the synergistic effects of agents like sirolimus with tacrolimus and cyclosporine.
• Evaluation of combination therapy strategies for GVHD management.

Main Results:

• Sirolimus demonstrates synergy with calcineurin inhibitors and may promote allograft tolerance.
• Mycophenolate mofetil (MMF) shows encouraging results in ongoing studies for acute and chronic GVHD prophylaxis and treatment.
• Various monoclonal antibodies and other agents are discussed in the context of GVHD.

Conclusions:

• Combination regimens disrupting multiple GVHD phases are likely most effective for prevention.
• Combination therapy for established GVHD is expected to outperform monotherapy.
• Novel treatment modalities offer improved prospects for managing acute and chronic GVHD.